Nomura Asset Management Co. Ltd. Buys 4,409 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Nomura Asset Management Co. Ltd. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,278 shares of the biopharmaceutical company’s stock after purchasing an additional 4,409 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $37,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Ameriflex Group Inc. bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $32,000. Aster Capital Management DIFC Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $36,000. Newbridge Financial Services Group Inc. bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $39,000. Finally, Eastern Bank bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $42,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 2.1%

Shares of ALNY stock opened at $295.63 on Tuesday. The stock has a 50 day moving average of $309.07 and a 200 day moving average of $353.02. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market cap of $39.47 billion, a P/E ratio of 80.77 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a twelve month low of $284.28 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% on a year-over-year basis. During the same period last year, the business earned ($0.44) earnings per share. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Insiders Place Their Bets

In related news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Needham & Company LLC dropped their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Citigroup started coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $463.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.